AgomAb Therapeutics is based in Ghent, Belgium. It has raised $189M in total funding. Latest round: Series D.
AgomAb Therapeutics is based in Ghent, Belgium. AgomAb Therapeutics has raised $189M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series D announced in October 2024. The round record for AgomAb Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Sanofi, Invus, Fidelity Management & Research Company, EQT Life Sciences, Canaan, Dawn Biopharma. 6 distinct backers are named across the disclosed rounds.
Round data for AgomAb Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Ghent and backer lists below.
The investor deck AgomAb Therapeutics used to raise — 2023, Series B, 21-slide deck is broken down slide by slide, including the slides it leads with and the questions it leaves open.
Company funding database · Investor directory · Founder database · Mega-rounds 2026